Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Blue Mesa Health

- PMLiVE

Sanofi and T1D Exchange collaborate to understand needs of children living with diabetes

Aims to deliver recommendations for better disease management and patient outcomes

- PMLiVE

EU approval for AZ/BMS’ first-in-class diabetes drug Forxiga

First SGLT2 inhibitor to be approved for marketing anywhere in the world

- PMLiVE

WHO launches framework to monitor non-communicable diseases

Will measure success of efforts to reduce rates of cancer, diabetes, lung conditions and heart disease

- PMLiVE

Merck & Co stops development of Januvia, atorvastatin combo

Company spokesperson claims decision is for “business reasons”

- PMLiVE

Lilly launches diabetes partnership programme in South Africa

Partners with Project Hope and Donald Woods Foundation

- PMLiVE

Novo Nordisk’s new insulin moves closer to US approval

Follows recommendation in Europe

- PMLiVE

Guide to gamification

How to execute digital: Using gaming as part of a pharma marketing campaign

- PMLiVE

Boehringer-Lilly win expanded European licence for Trajenta

Type 2 diabetes drug approved as add-on to insulin in adults

- PMLiVE

Diabetes care recognised at UK awards

Joint working between pharma, NHS and patient organisations key among winners at QiC Diabetes 2012

- PMLiVE

Novo wins CHMP backing for Tresiba and diabetes first

EMA advisors recommend approval of once-daily at unique higher strength

- PMLiVE

Data-driven pharma marketing

The most successful organisations of the future will be the ones that are able to ride the ‘data tsunami’ to gain a competitive advantage – and understanding data generated by...

- PMLiVE

NICE in U-turn on Novartis’ Lucentis in diabetic macular oedema

Patient access scheme influences draft recommendation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links